Chief investigator Professor Alan Burnett, from Cardiff Universitys School of Medicine, commented on the findings:
These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects.
Although there has been some controversy around the use of GO following its withdrawal in the US two years ago, these results appear extremely promising and suggest no such cause for concern if the appropriate dose is given. Crucially, this represents some of the first progress in treating AML patients of this age group for at least 20 years.
More top news
Those hoping for a sunny Easter weekend could be disappointed as forecasters are predicting bank holiday showers could be on their way.
The Labour Party has defended the sale of a mug bearing the words "controls on immigration" after it was mocked online.
We spring forward an hour at 1am on Sunday, to mark the start of British Summer Time.